Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2016 Apr 1;126(4):1603–1604. doi: 10.1172/JCI87364

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

John S Millar, Gissette Reyes-Soffer, Patricia Jumes, Richard L Dunbar, Emil M deGoma, Amanda L Baer, Wahida Karmally, Daniel S Donovan, Hashmi Rafeek, Laura Pollan, Junichiro Tohyama, Amy O Johnson-Levonas, John A Wagner, Stephen Holleran, Joseph Obunike, Yang Liu, Rajasekhar Ramakrishnan, Michael E Lassman, David E Gutstein, Henry N Ginsberg, Daniel J Rader
PMCID: PMC4811110  PMID: 27035815

Original citation: J Clin Invest. 2015;125(6):2510–2522. doi:10.1172/JCI80025.

Citation for this corrigendum: J Clin Invest. 2016;126(4):1603–1604. doi:10.1172/JCI87364.

In Table 4, the units for ApoC-III conc. were incorrect. The correct table is below.

Table 4. Factors known to be associated with ApoB clearance: mean baseline values, percentage change from baseline, and between-period differences for subjects in the total population and by panel.

graphic file with name JCI87364.t4.jpg

Open in a new tab

The authors regret the error.

Footnotes

See the related article beginning on page 2510.

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES